Early Detection, Diagnosis, and Staging of Lung Neuroendocrine Tumors
Know the signs and symptoms of lung neuroendocrine tumors (NETs). Find out how lung NETs are tested for, diagnosed, and staged.
Can lung neuroendocrine tumors be found early?
Because NETs usually start out very small and grow and spread slowly, most NETs are found in an early or localized stage, often before they cause any symptoms or problems. NETs often are found by accident, when tests are done for other reasons.
Screening is the use of tests or exams to find a disease in people who don’t have symptoms. Lung NETs are not common, and there are no widely recommended screening tests for these tumors in most people.
People with multiple endocrine neoplasia type 1 (MEN1) are at increased risk for these tumors, and some doctors recommend they have CT scans of the chest every 2-5 years.
Stages and outlook for lung neuroendocrine tumors
After a diagnosis with a lung NET, many people want to understand what to expect. The stage of a cancer describes how much cancer is in the body. It helps determine how serious the cancer is and how best to treat it.
Survival rates are a way to measure how many people survive a certain type of cancer over time. Survival rates are often reported as 5-year survival rates, which refer to the percentage of people who live at least 5 years after their cancer diagnosis.
Tests for lung neuroendocrine tumors
Certain signs and symptoms might suggest that a person could have a lung NET, but tests are needed to confirm the diagnosis.
Medical history and physical exam
You will be asked questions about your general health, lifestyle habits, symptoms, and risk factors. The doctor may ask about symptoms that could be caused by carcinoid syndrome (a series of symptoms caused by some lung NETs), as well as those that might be caused by a tumor in the lungs.
Some patients with NETs also have cancers or benign tumors of other organs, so doctors may ask about symptoms that might suggest other tumors are present. A thorough physical exam will provide information about signs of NETs and other health problems.
If your medical history and physical exam give the doctor reason to suspect you might have a lung NET, some tests will be ordered to find out if the disease is present. These might include imaging tests, lab tests, and other procedures.
Imaging tests
Imaging tests are used to create pictures of the inside of the body. Imaging tests can be done for a number of reasons, including:
- To help find out if a suspicious area might be cancer
- To learn how far cancer has spread
- To help determine if treatment is working
- To look for possible signs of cancer coming back after treatment
A chest x-ray is often the first imaging test a doctor orders if a lung problem is suspected. It might be able to show if there is a tumor in the lung. But some tumors that are small or are in places where they are covered by other organs in the chest may not show up on a chest x-ray. If your doctor is still suspicious or if something is seen on the chest x-ray, a CT scan may be ordered.
A CT scan uses x-rays taken from different angles, which are combined by a computer to make detailed pictures of the organs. This test is most often used to look at the chest and/or belly (abdomen) to see if lung NETs have spread to other organs. It can also be used to guide a biopsy needle into an area of concern.
MRI scans create detailed images of soft tissues in the body using radio waves and strong magnets. A dye (gadolinium) may be injected into a vein before the scan to show details better. An MRI scan sometimes can see cancer that has spread to the liver better than a CT scan.
Scans using small amounts of radioactivity and special cameras can be helpful in looking for lung NETs. They can help find tumors or look for areas of cancer spread if doctors aren’t sure where it is in the body.
Somatostatin receptor targeted PET-CT (SSTR-PET/CT): This test can be helpful in finding lung NETs, but is not always reliable, especially for high-grade tumors. The somatostatin receptor (SSTR) is commonly found on NETs, but some NETs do not have the SSTR and therefore are not seen on SSTR-PET/CT.
To identify the presence of lung NETs, dotatate or dotatoc, man-made molecules that bind to the SSTR, are linked to a radioactive tracer. 68Ga-dotatate, 64Cu-dotatate, and 68Ga-dotatoc are the agents used.
When one of these agents attaches to the SSTR on cancer cells, the radioactive tracer can be seen on a PET scan.
This type of imaging scan can be helpful in two ways:
- It can show doctors where the lung NET is and if the NET has spread to other parts of the body.
- It can show doctors if treating the NET with a somatostatin analog, such as octreotide or lanreotide, or Peptide Receptor Radionuclide Therapy (PRRT) would be helpful.
The SSTR-PET scan can be done with a CT scan to give clearer images. A dye may be injected into your vein before the CT scan to show details better.
Somatostatin receptor targeted PET-MRI (SSTR-PET/MRI): The SSTR-PET scan can be done with an MRI scan, as opposed to a CT scan. The decision on which scan to use is based on which organ needs to be viewed. For example, if there is concern that cancer cells have spread to the liver, SSTR-PET/MRI may be a preferred option.
Bronchoscopy is a procedure a doctor uses to look inside the lungs. This is done with a bronchoscope, a thin, flexible tube with a light and a small camera on the end. The tube is put in through your nose or mouth, down your throat, into your trachea (windpipe), and into the airways (bronchi and bronchioles) of your lungs.
If a tumor is found, small pieces can be removed (biopsied) through the tube. The doctor can also sample cells from the lining of the airways by wiping a tiny brush over the surface of the tumor (bronchial brushing) or by rinsing the airways with sterile saltwater and then collecting it (bronchial washing).
This test uses an endoscope with a small ultrasound probe on the end that is passed down into the windpipe. This probe releases sound waves and then uses the echoes that bounce back to create images.
EBUS can be used to see where a tumor has grown inside the lungs and if certain lymph nodes are enlarged. It can also help the doctor guide a needle into a lymph node, tumor, or another suspicious area to do a biopsy.
You will be sedated for this test, so you will need someone to take you home.
Biopsy
In many cases, the only way to know for sure if a person has a lung NET is to remove cells from the tumor (biopsy) and look at them in the lab. This procedure can be done in different ways. You can read more about biopsies and how they are tested in Biopsy and Cytology Tests.
For this type of biopsy, a doctor inserts a thin, hollow needle through the skin over lungs and into the tumor to remove a small piece. This is known as a CT-guided transthoracic needle aspiration. The doctor guides the needle into place using images from CT scans.
Doctors can biopsy a tumor during an endoscopy, such as a bronchoscopy.
Rarely, an endoscopic biopsy or a CT-guided needle biopsy will not be able to get enough tissue to identify the type of tumor. In such cases, surgery may be needed to remove a tissue sample.
Surgical biopsies are done much less often now than in the past, since NETs are mostly diagnosed using needle biopsies.
Questions to ask if you have lung neuroendocrine tumors
- Where in my lungs is the NET located?
- Can you explain my pathology report (laboratory test results) to me?
- Has the cancer spread beyond where it started?
- What is the cancer’s stage (extent), and what does that mean?
- Will I need other tests before we can decide on treatment?
- Will I need to see any other doctors or health professionals?
- If I’m concerned about the costs and insurance coverage for my diagnosis and treatment, who can help me?
- Written by
- References
Developed by the American Cancer Society medical and editorial content team with medical review and contribution by the American Society of Clinical Oncology (ASCO).
Horn L, Eisenberg R, Guis D et al. Chapter 72: Cancer of the Lung – Non-small Cell Lung Cancer and Small Cell Lung. In: Niederhuber JE, Armitage JO, Dorshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, Pa. Elsevier: 2014.
Melosky B. Low Grade Neuroendocrine Tumors of the Lung. Frontiers in Oncology. 2017;7:119. doi:10.3389/fonc.2017.00119.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. V.3.2025. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf on September 30, 2025.
Oliveira AM, Tazelaar HD, Wentzlaff KA, Kosugi NS, Hai N, Benson A, Miller DL, Yang P. Familial pulmonary carcinoid tumors. Cancer. 2001 Jun 1;91(11):2104-9.
So A, Pointon O, Hodgson R, Burgess J. An assessment of 18 F-FDG PET/CT for thoracic screening and risk stratification of pulmonary nodules in multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf). 2018 May;88(5):683-691. doi: 10.1111/cen.13573.
Last Revised: December 17, 2025
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
American Cancer Society Emails
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.


